092 Real-World data on efficacy, safety and persistence of dupilumab: An analysis from the TREATgermany registry

In clinical trials safety and efficacy of therapies are tested in selected patient populations, whereas registries like the atopic dermatitis (AD) multicenter registry TREATgermany provide longitudinal data under real-life conditions. this analysis 1211 patients (data release July 2021) with moderate to severe AD was used, following mean scores at baseline: EASI 16.1±12.9, IGA 3.2±1.1, itch NRS 5.7±2.8, POEM 16.8±7.6, DLQI 11.8±7.8. During observation 76.3% received least one systemic treatment for AD; a proportion 81.9% dupilumab most used drug 2021. contrast, until launch Germany December 2017 only 36.8% had therapy, cyclosporine being often prescribed one. Dupilumab (n=369) (n=41) treatments showed comparable effectiveness. Exemplary month 12 after initiation, EASI50, EASI75 EASI90 were 86.3%, 68.0% 39.1%, respectively. Discontinuation rates considerably higher. While discontinued 5.0% 11.4% 24, 77.8% 100%, Low persistence may also reflect adherence guideline recommendations on duration its continuous use. Adverse events reported 42.5% all dupilumab-treated patients, ocular side effects frequent (29.8%). These results demonstrate that has rapidly emerged as commonly Germany, shows robust long-term safety.